163 related articles for article (PubMed ID: 33235070)
1. Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis.
Lin M; Zhang S; Zhang M; Shi J; Zhang C; Luo R; You J; Sun J; Zhang J; Gao F
Medicine (Baltimore); 2020 Nov; 99(48):e23103. PubMed ID: 33235070
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical preparations of Periplaneta americana (KangFuXin liquid) in the treatment of pressure ulcer: A meta-analysis.
Wang J; Zhong L; Bo Y; Luo N; Hao P
Int Wound J; 2023 Sep; 20(7):2855-2868. PubMed ID: 36851877
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis.
Zhu HD; Wang H; Xia XM; Xu SM; Lan Y
Chin Med J (Engl); 2013 Aug; 126(16):3146-50. PubMed ID: 23981627
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis.
He HS; Li BY; Chen QT; Song CY; Shi J; Shi B
Med Sci Monit; 2019 Feb; 25():1169-1176. PubMed ID: 30755541
[TBL] [Abstract][Full Text] [Related]
5. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Li HB; Chen MY; Qiu ZW; Cai QQ; Li DT; Tang HM; Chen XL
Medicine (Baltimore); 2018 May; 97(21):e10807. PubMed ID: 29794765
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
Chen L; Chen Y; Li B
Sci Rep; 2016 Sep; 6():32126. PubMed ID: 27581096
[TBL] [Abstract][Full Text] [Related]
8. Gastroprotective effects of Kangfuxin against water-immersion and restraint stress-induced gastric ulcer in rats: roles of antioxidation, anti-inflammation, and pro-survival.
Lu S; Wu D; Sun G; Geng F; Shen Y; Tan J; Sun X; Luo Y
Pharm Biol; 2019 Dec; 57(1):770-777. PubMed ID: 31696757
[No Abstract] [Full Text] [Related]
9. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
10. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash RP; Rais R; Srinivas NR
Xenobiotica; 2018 Apr; 48(4):422-432. PubMed ID: 28294690
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Hawkey CJ; Atherton JC; Treichel HC; Thjodleifsson B; Ravic M
Aliment Pharmacol Ther; 2003 Apr; 17(8):1065-74. PubMed ID: 12694089
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.
Luo JC; Huang KW; Leu HB; Chen LC; Hou MC; Li CP; Lu CL; Lin HC; Lee FY; Lee SD
Aliment Pharmacol Ther; 2011 Sep; 34(5):519-25. PubMed ID: 21726257
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Liu MK; Wu IC; Lu CY; Kuo CH; Yu FJ; Liu CJ; Hsu PI; Hsu WH; Su YC; Chen A; Wu DC; Kuo FC; Chen JJ
Kaohsiung J Med Sci; 2013 Jul; 29(7):379-84. PubMed ID: 23768702
[TBL] [Abstract][Full Text] [Related]
15. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.
Hu JL; Yang J; Zhou YB; Li P; Han R; Fang DC
Saudi J Gastroenterol; 2017; 23(5):275-280. PubMed ID: 28937021
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer.
Zou JB; Zhang XF; Shi YJ; Tai J; Wang Y; Liang YL; Wang F; Cheng JX; Wang J; Guo DY
Evid Based Complement Alternat Med; 2019; 2019():1324969. PubMed ID: 31662770
[TBL] [Abstract][Full Text] [Related]
17. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
Ji S; Kim HS; Kim JW; Jee MK; Park KW; Uh Y; Lee DK; Song JS; Baik SK; Kwon SO
J Gastroenterol Hepatol; 2006 Sep; 21(9):1381-7. PubMed ID: 16911680
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.
Kinoshita Y; Hongo M; Kusano M; Furuhata Y; Miyagishi H; Ikeuchi S;
Intern Med; 2017; 56(10):1131-1139. PubMed ID: 28502925
[TBL] [Abstract][Full Text] [Related]
20. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
